down arrow

Summit Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US86627T1088
USD
18.81
1.56 (9.04%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

18.1918.99

52 Week

15.5536.91
Valuation
Technical
Day's Volume

CASH

2.78 M

Shareholding (Mar 2025)

FII

1.83%

Held by 99 FIIs

DII

93.06%

Held by 16 DIIs

Promoter

0.09%

How big is Summit Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Summit Therapeutics, Inc. has a market capitalization of 14,741.92 million, classifying it as a Small Cap company, with net sales of 0.00 million and a net profit of -240.75 million for the latest four quarters. As of December 2024, shareholder's funds were 388.75 million and total assets were 435.56 million.

Market Cap: As of Jun 18, Summit Therapeutics, Inc. has a market capitalization of 14,741.92 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -240.75 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds amounted to 388.75 million, while total assets were reported at 435.56 million.

Read More

What does Summit Therapeutics, Inc. do?

22-Jun-2025

Summit Therapeutics, Inc. develops treatments for infectious diseases in the Pharmaceuticals & Biotechnology sector. It has a market cap of approximately $14.74 billion and reported a net profit loss of $63 million as of March 2025.

Overview: <BR>Summit Therapeutics, Inc. is focused on developing treatments for infectious diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Market cap: USD 14,741.92 Million (Small Cap) <BR>Net Profit: -63 Million (Quarterly Results - Mar 2025)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -65.56% <BR>Price to Book: 42.81<BR><BR>Contact Details: <BR>Address: One Broadway, 14Th Floor, CAMBRIDGE MA: 02142 <BR>Tel: 1 617 5147149 <BR>Fax: 1 302 6555049

Read More

Who are in the management team of Summit Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Summit Therapeutics, Inc. includes Dr. Elaine Stracker as Executive Director and Mr. Rainer Erdtmann as Non-Executive Independent Director.

As of March 2022, the management team of Summit Therapeutics, Inc. includes Dr. Elaine Stracker, who serves as the Executive Director, and Mr. Rainer Erdtmann, who is a Non-Executive Independent Director.

Read More

Is Summit Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 9, 2022, Summit Therapeutics, Inc. is overvalued with a valuation grade of "does not qualify," reflecting significant financial deterioration, highlighted by a Price to Book Value ratio of 44.41, an EV to EBIT of -63.40, and a concerning -65.56% Return on Equity, despite a strong stock performance of 157.12% over the past year compared to the S&P 500's 10.26%.

As of 9 November 2022, the valuation grade for Summit Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, with a Price to Book Value ratio of 44.41 and an EV to EBIT of -63.40, reflecting its loss-making status. Additionally, the Return on Equity (ROE) stands at a concerning -65.56%, which further underscores the challenges the company faces.<BR><BR>In comparison to its peers, Summit Therapeutics, Inc. shows a stark contrast; for instance, Merus NV has a P/E ratio of -14.25 and an EV to EBITDA of -11.71, while Rhythm Pharmaceuticals, Inc. has a P/E of -22.45 and an EV to EBITDA of -22.69. These ratios highlight that Summit is not only underperforming relative to its peers but also lacks a viable valuation framework. Despite recent strong stock performance against the S&P 500, with a 1-year return of 157.12% compared to the index's 10.26%, the underlying financial metrics suggest that the stock is not justified at its current price level.

Read More

Is Summit Therapeutics, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Summit Therapeutics, Inc. shows a mildly bullish trend driven by daily moving averages, despite mixed signals from MACD and Bollinger Bands, with a year-to-date return of 24.12% outperforming the S&P 500's 14.18%.

As of 3 October 2025, the technical trend for Summit Therapeutics, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD is bearish and the monthly MACD is mildly bearish. The Bollinger Bands show a mixed signal with the weekly being mildly bearish and the monthly bullish. Overall, the Dow Theory suggests a mildly bullish trend on the weekly timeframe, but no trend on the monthly.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 on a weekly basis with a return of 4.68% compared to 1.09%, but it has underperformed over the past month with a return of -14.74% against the S&P 500's 4.15%. Year-to-date, the stock shows a strong return of 24.12%, exceeding the S&P 500's 14.18%. <BR><BR>Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly Dow Theory.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 14,445 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.14

stock-summary
Return on Equity

-287.57%

stock-summary
Price to Book

55.68

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-566 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.03%
0%
-20.03%
6 Months
-8.78%
0%
-8.78%
1 Year
5.85%
0%
5.85%
2 Years
783.1%
0%
783.1%
3 Years
2311.54%
0%
2311.54%
4 Years
276.2%
0%
276.2%
5 Years
286.24%
0%
286.24%

Summit Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Summit Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Summit Therapeutics, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD is bearish and the monthly MACD is mildly bearish. The Bollinger Bands show a mixed signal with the weekly being mildly bearish and the monthly bullish. Overall, the Dow Theory suggests a mildly bullish trend on the weekly timeframe, but no trend on the monthly. In terms of performance, the stock has outperformed the S&P 500 on a weekly basis with a return of 4.68% compared to 1.09%, but it has underperformed over the past month with a return of -14.74% against the S&P 500's 4.15%. Year-to-date, the stock shows a strong return of 24.12%, exceeding the S&P 500's 14.18%. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly Dow Theory....

Read More

Is Summit Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Summit Therapeutics, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly and monthly MACD and KST readings are mildly bearish. The Bollinger Bands show a bullish signal on the monthly timeframe, contrasting with the weekly mildly bearish indication. Overall, the Dow Theory suggests a mildly bullish trend on the weekly basis, but no trend on the monthly. In terms of performance, the stock has outperformed the S&P 500 over the past week and year-to-date, with returns of 2.29% and 20.09% respectively, while it lagged behind the index over the past month and year. The current technical stance is mildly bullish, driven primarily by the daily moving averages and the Dow Theory....

Read More

Is Summit Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Summit Therapeutics, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are both mildly bearish. The Bollinger Bands show a bullish signal on the monthly timeframe, which contrasts with the mildly bearish indicators on the weekly timeframe. Overall, the mixed signals suggest a cautious bullish outlook. In terms of performance, the stock has outperformed the S&P 500 over the past week with a return of 2.29% compared to the S&P 500's 1.09%, but it has underperformed over the past month with a return of -8.89% versus the S&P 500's 4.15%. Year-to-date, the stock has returned 20.09%, outperforming the S&P 500's 14.18%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-258.50%
EBIT to Interest (avg)
-47.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.43%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
44.41
EV to EBIT
-63.40
EV to EBITDA
-63.43
EV to Capital Employed
-1085.28
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-65.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 49 Schemes (5.02%)

Foreign Institutions

Held by 99 Foreign Institutions (1.83%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -799.36% vs -2.78% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-568.40",
          "val2": "-66.80",
          "chgp": "-750.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-565.70",
          "val2": "-62.90",
          "chgp": "-799.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 64.01% vs -680.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-211.20",
          "val2": "-87.70",
          "chgp": "-140.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.70",
          "val2": "16.50",
          "chgp": "-47.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.00",
          "val2": "-520.90",
          "chgp": "97.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-221.30",
          "val2": "-614.90",
          "chgp": "64.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-568.40
-66.80
-750.90%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-565.70
-62.90
-799.36%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -799.36% vs -2.78% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-211.20
-87.70
-140.82%
Interest
8.70
16.50
-47.27%
Exceptional Items
-15.00
-520.90
97.12%
Consolidate Net Profit
-221.30
-614.90
64.01%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 64.01% vs -680.33% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Summit Therapeutics, Inc. stock-summary
stock-summary
Summit Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Summit Therapeutics Inc. is focused on developing treatments for infectious diseases. The Company uses its Discuva platform, an antibiotic discovery engine to develop antibiotics. It is initially focused on Clostridioides difficile infections (CDI). Its platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. Ridinilazole is its new mechanism antibiotic, which is being developed for CDI.
Company Coordinates stock-summary
Company Details
One Broadway, 14Th Floor , CAMBRIDGE MA : 02142
stock-summary
Tel: 1 617 5147149
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."